drugset
drugset / Trial / NCT05545124

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

NCT05545124 ↗

Phase 2 Unknown 32 enrolled Henan Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

To explore the safety and preliminary efficacy of donafenib combined with tislelizumab in adjuvant therapy after radical surgical resection of primary hepatocellular carcinoma with high risk of recurrence.

Timeline

Start
2022-11
Primary completion
2023-11
Completion
2024-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Donafenib Small molecule 100 mg —
Subject Tislelizumab Monoclonal antibody 200 mg —

Indications

hepatocellular carcinoma